Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 4/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.34 |
| ▸ | REN | P00797 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | PNMT | P11086 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21192543 | 0.98 | BACE1 (0.33) | BACE1BACE2RENAPPPNMT | |
| Hydrochloric Acid SCHEMBL14576582 | 0.98 | BACE1 (0.33) | BACE1BACE2RENAPPPNMT | |
| SCHEMBL11790557 | 0.75 | BACE1 (0.33) | BACE1BACE2 | |
| SCHEMBL11264366 | 0.60 | LMNA (0.38) | BACE1BACE2RENAPPPNMT | |
| SCHEMBL4266501 | 0.60 | MAOA (0.33) | BACE1BACE2RENAPPPNMT | |
| SCHEMBL216066 | 0.60 | LMNA (0.35) | BACE1BACE2 | |
| SCHEMBL5607855 | 0.59 | BACE1 (0.33) | BACE1BACE2RENAPP | |
| SCHEMBL5536641 | 0.59 | BACE1 (0.33) | BACE1BACE2RENAPP | |
| SCHEMBL27683781 | 0.57 | BACE1 (0.37) | BACE1BACE2RENAPPPNMT | |
| SCHEMBL3969821 | 0.57 | BACE1 (0.32) | BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114790442-A | Method for regulating osteogenic differentiation and apoptosis of bone marrow mesenchymal stem cells by using SNHG5 | 徐州医科大学 | 2022-07-26 | — | — | CN | claimed |
| CN-118516374-A | Application of garlic AsWRKY transcription factor in improving alliin content in garlic callus | 江苏师范大学 | 2024-08-20 | — | — | CN | disclosed |
| CN-117210480-A | Nucleotide sequences expressing exosome-anchored proteins for use as vaccines | 国家高等卫生院 | 2023-12-12 | — | — | CN | disclosed |
| CN-116783210-A | Nkd2 as target for treating renal fibrosis | 亚琛工业大学 | 2023-09-19 | — | — | CN | disclosed |
| US-11559571-B2 | Nucleotide sequence expressing an exosome-anchoring protein for use as vaccine | ISTITUTO SUPERIORS DI SANITÀ (IT) | 2023-01-24 | — | — | US | disclosed |
| CN-114790442-A | Method for regulating osteogenic differentiation and apoptosis of bone marrow mesenchymal stem cells by using SNHG5 | 徐州医科大学 | 2022-07-26 | — | — | CN | disclosed |
| EP-3049056-B2 | ANTIFUNGAL TOPICAL COMPOSITION AND METHODS OF TREATMENT | BLUEBERRY THERAPEUTICS LTD (GB) | 2022-06-01 | — | — | EP | disclosed |
| US-20220133640-A1 | COMPOSITION AND METHODS OF TREATMENT | BLUEBERRY THERAPEUTICS LTD (GB) | 2022-05-05 | — | — | US | disclosed |
| US-11185511-B2 | Antifungal topical composition and methods of treatment | BLUEBERRY THERAPEUTICS LIMITED (GB) | 2021-11-30 | — | — | US | disclosed |
| EP-3022225-B1 | TRANSTHYRETIN AMYLOID-SELECTIVE AND POLYREACTIVE CATABODIES | UNIV TEXAS (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-0960203-A1 | MAMMALIAN CHK1 EFFECTOR CELL-CYCLE CHECKPOINT PROTEIN KINASE MATERIALS AND METHODS | ICOS CORPORATION (US) | 1999-12-01 | — | — | EP | disclosed |
| US-5910568-A | GENETICALLY ENGINEERED SYNTHETIC POLYPEPTIDE THAT IS INVOLVED RESTORING THE JOINING CAPACITY OF SEMEN AND OOCYTE; CONTRACEPTIVES; FERTILITY TREATMENTS | THE PENN STATE RESEARCH FOUNDATION (US) | 1999-06-08 | — | — | US | disclosed |
| WO-1999011795-A1 | MAMMALIAN CHK1 EFFECTOR CELL-CYCLE CHECKPOINT PROTEIN KINASE MATERIALS AND METHODS | ICOS CORPORATION (US) | 1999-03-11 | — | — | WO | disclosed |
| EP-0900276-A1 | NOVEL CYCLIN-SELECTIVE UBIQUITIN CARRIER POLYPEPTIDES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1999-03-10 | — | — | EP | disclosed |
| EP-0647271-B1 | GENE FOR ATAXIA-TELANGIECTASIA COMPLEMENTATION GROUP D (ATDC) | UNIV CALIFORNIA (US) | 1999-01-20 | — | — | EP | disclosed |
| EP-0876610-A1 | A METHOD AND USE OF POLYPEPTIDE IN SPERM-EGG BINDING TO ENHANCE OR DECREASE FERTILITY | THE PENN STATE RESEARCH FOUNDATION (US) | 1998-11-11 | — | — | EP | disclosed |
| WO-1997037027-A1 | NOVEL CYCLIN-SELECTIVE UBIQUITIN CARRIER POLYPEPTIDES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1997-10-09 | — | — | WO | disclosed |
| WO-1997025620-A1 | A METHOD AND USE OF POLYPEPTIDE IN SPERM-EGG BINDING TO ENHANCE OR DECREASE FERTILITY | THE PENN STATE RESEARCH FOUNDATION (US) | 1997-07-17 | — | — | WO | disclosed |
| EP-0647271-A1 | GENE FOR ATAXIA-TELANGIECTASIA COMPLEMENTATION GROUP D (ATDC) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-04-12 | — | — | EP | disclosed |
| WO-1994000572-A2 | GENE FOR ATAXIA-TELANGIECTASIA COMPLEMENTATION GROUP D (ATDC) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1994-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133640-A1 | COMPOSITION AND METHODS OF TREATMENT | POLR1C, PIK3C3, DPM1 | BACE1 4225/4885BACE2 4218/4885REN 3862/4885 |
| US-11185511-B2 | Antifungal topical composition and methods of treatment | DPM1, POLR1C, TUBB3 | BACE1 2879/4885BACE2 1644/4885REN 4817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.